Published in the Green Journal, this registry study reported treatment outcomes of PBT for 309 patients with inoperable stage I-IIA NSCLC. With a median follow-up of 47 months, 3-year OS, PFS, and LF (local failure) were 69.6 %, 58.7 %, 13.3 %, respectively, for stage IA; 55.3 %, 41.6 %, 15.6 %, respectively, for stage IB; 33.9 %, 41.5 %, 25.6 %, respectively, for stage IIA. Grade ≥4 adverse events were not observed. Grade 3 toxicities were reported in 11 (4 %) patients including 6 with radiation pneumonitis. Of 46 patients with background interstitial pneumonia (IP), 6 (13 %) developed grade 2 radiation pneumonitis. The authors remarked that this study provided prospective real-world data and demonstrated a relatively low rate of IP in this subset of patients treated with PBT.